1. Home
  2. IZEA vs BTAI Comparison

IZEA vs BTAI Comparison

Compare IZEA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IZEA Worldwide Inc.

IZEA

IZEA Worldwide Inc.

N/A

Current Price

$3.69

Market Cap

78.8M

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

N/A

Current Price

$1.56

Market Cap

35.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IZEA
BTAI
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.8M
35.6M
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
IZEA
BTAI
Price
$3.69
$1.56
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$25.33
AVG Volume (30 Days)
56.0K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
$20,099,695.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.91
$261.81
P/E Ratio
$51.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.68
$1.17
52 Week High
$5.86
$8.08

Technical Indicators

Market Signals
Indicator
IZEA
BTAI
Relative Strength Index (RSI) 50.84 46.64
Support Level $3.48 $1.50
Resistance Level $3.85 $2.18
Average True Range (ATR) 0.17 0.14
MACD 0.04 0.00
Stochastic Oscillator 57.58 31.58

Price Performance

Historical Comparison
IZEA
BTAI

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: